- Home
- WFRD vs BLTE Comparison
WFRD vs BLTE Comparison
Compare WFRD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- BLTE
- Stock Information
- Founded
- WFRD 1941
- BLTE 2018
- Country
- WFRD United States
- BLTE United States
- Employees
- WFRD N/A
- BLTE N/A
- Industry
- WFRD Metal Fabrications
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- BLTE Health Care
- Exchange
- WFRD Nasdaq
- BLTE Nasdaq
- Market Cap
- WFRD 4.1B
- BLTE 4.1B
- IPO Year
- WFRD N/A
- BLTE 2022
- Fundamental
- Price
- WFRD $71.87
- BLTE $124.75
- Analyst Decision
- WFRD Strong Buy
- BLTE Strong Buy
- Analyst Count
- WFRD 8
- BLTE 5
- Target Price
- WFRD $86.13
- BLTE $105.00
- AVG Volume (30 Days)
- WFRD 919.2K
- BLTE 96.5K
- Earning Date
- WFRD 10-21-2025
- BLTE 11-10-2025
- Dividend Yield
- WFRD 1.40%
- BLTE N/A
- EPS Growth
- WFRD N/A
- BLTE N/A
- EPS
- WFRD 5.52
- BLTE N/A
- Revenue
- WFRD $4,970,000,000.00
- BLTE N/A
- Revenue This Year
- WFRD N/A
- BLTE N/A
- Revenue Next Year
- WFRD N/A
- BLTE N/A
- P/E Ratio
- WFRD $12.93
- BLTE N/A
- Revenue Growth
- WFRD N/A
- BLTE N/A
- 52 Week Low
- WFRD $36.74
- BLTE $49.00
- 52 Week High
- WFRD $87.63
- BLTE $125.01
- Technical
- Relative Strength Index (RSI)
- WFRD 53.08
- BLTE 75.17
- Support Level
- WFRD $68.86
- BLTE $108.75
- Resistance Level
- WFRD $73.79
- BLTE $124.73
- Average True Range (ATR)
- WFRD 2.96
- BLTE 7.56
- MACD
- WFRD -0.49
- BLTE 0.44
- Stochastic Oscillator
- WFRD 34.03
- BLTE 96.99
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.